KPRX Historical PE Ratio image   This KPRX PE ratio history page last updated 6/21/2022
KPRX PE History Chart
PeriodPriceGAAPTTMPE
Q4 2021
4/15/2022
NA-0.78-1.83NA
Q3 2021
11/15/2021
1.52-0.29-1.57NA
Q2 2021
8/12/2021
1.73-0.39-1.72NA
Q1 2021
5/12/2021
4.03-0.37-1.71NA
Q4 2020
3/25/2021
5.07-0.52-1.77NA
Q3 2020
11/9/2020
3.30-0.44-2.01NA
Q2 2020
8/6/2020
4.00-0.38-2.72NA
Q1 2020
5/6/2020
5.16-0.43-2.94NA
Q4 2019
3/4/2020
5.65-0.76-2.36NA
Q3 2019
11/7/2019
3.76-1.15-2.35NA
Q2 2019
8/8/2019
0.20-0.60-2.25NA
Q1 2019
5/8/2019
0.260.15-2.70NA
Q4 2018
3/1/2019
0.44-0.75-4.95NA
Q3 2018
11/13/2018
0.42-1.05-7.80NA
Q2 2018
8/3/2018
0.56-1.05-10.35NA
Q1 2018
5/11/2018
0.53-2.10-13.50NA
Q4 2017
3/2/2018
0.59-3.60-15.60NA
Q3 2017
11/14/2017
1.06-3.60-17.70NA
Q2 2017
8/7/2017
1.14-4.20-19.50NA
Q1 2017
5/8/2017
1.89-4.20-22.20NA
Q4 2016
2/23/2017
2.81-5.70-22.65NA
Q3 2016
11/2/2016
1.42-5.40-20.55NA
Q2 2016
8/10/2016
2.06-6.90NANA
Q1 2016
5/13/2016
3.14-4.65NANA
Q4 2015
3/29/2016
3.06-3.60NANA
KPRX Historical PE Ratio Chart
PeriodPriceGAAPAnnualizedPE
Q4 2021
4/15/2022
NA-0.78-3.12NA
Q3 2021
11/15/2021
1.52-0.29-1.16NA
Q2 2021
8/12/2021
1.73-0.39-1.56NA
Q1 2021
5/12/2021
4.03-0.37-1.48NA
Q4 2020
3/25/2021
5.07-0.52-2.08NA
Q3 2020
11/9/2020
3.30-0.44-1.76NA
Q2 2020
8/6/2020
4.00-0.38-1.52NA
Q1 2020
5/6/2020
5.16-0.43-1.72NA
Q4 2019
3/4/2020
5.65-0.76-3.04NA
Q3 2019
11/7/2019
3.76-1.15-4.60NA
Q2 2019
8/8/2019
0.20-0.60-2.40NA
Q1 2019
5/8/2019
0.260.150.600.4
Q4 2018
3/1/2019
0.44-0.75-3.00NA
Q3 2018
11/13/2018
0.42-1.05-4.20NA
Q2 2018
8/3/2018
0.56-1.05-4.20NA
Q1 2018
5/11/2018
0.53-2.10-8.40NA
Q4 2017
3/2/2018
0.59-3.60-14.40NA
Q3 2017
11/14/2017
1.06-3.60-14.40NA
Q2 2017
8/7/2017
1.14-4.20-16.80NA
Q1 2017
5/8/2017
1.89-4.20-16.80NA
Q4 2016
2/23/2017
2.81-5.70-22.80NA
Q3 2016
11/2/2016
1.42-5.40-21.60NA
Q2 2016
8/10/2016
2.06-6.90-27.60NA
Q1 2016
5/13/2016
3.14-4.65-18.60NA
Q4 2015
3/29/2016
3.06-3.60-14.40NA
Quotes delayed 20 minutes

Email EnvelopeFree KPRX Email Alerts:
Get Dividend Alerts
Get SEC Filing Alerts
10 Most Oversold S&P 500 Stocks
10 Most Overbought S&P 500 Stocks
10 ETFs With Stocks Insiders Are Buying
10 ETFs With Most Upside To Targets
The DividendRank Top 25
Warren Buffett Dividend Stocks
10 Cheap Dividend Stocks Under $10
10 Top DividendRank'ed Energy Stocks
The 10 Highest Yielding Preferred Stocks
The 10 Highest Yielding Preferred Stocks
The 15 Most Active S&P Call & Put Options
Kiora Pharmaceuticals (KPRX) is categorized under the Healthcare sector; to help you further research PE history across stocks, below are some other companies in the same sector:

KPTI PE Ratio History
KRBP PE Ratio History
KRMD PE Ratio History
KRON PE Ratio History
KROS PE Ratio History
KRTX PE Ratio History
KRYS PE Ratio History
KTRA PE Ratio History
KTTA PE Ratio History
KURA PE Ratio History
On this page we presented the KPRX PE Ratio History information for Kiora Pharmaceuticals' stock. The average KPRX PE ratio history based on using the annualized quarterly earnings result at each measurement period (for the "E" in the PE calculation; and the closing price on earnings date as the "P") is 0.4. Meanwhile, using the trailing twelve month (TTM) quarterly earnings result as our method of calculation the "E" value at each measurement period, the average KPRX PE ratio history based on this TTM earnings result method is NA. Note: any PE calculations involving negative earnings were discarded as not meaningful.

Let's now compare this KPRX PE ratio history result, against the recent PE: when this page was posted on 6/17/2022, the most recent closing price for KPRX had been 0.39, and the most recent quarterly earnings result, annualized, was 0.6. Meanwhile, the most recent TTM earnings summed to NA. From these numbers, we calculate the recent KPRX PE on 6/17/2022 based on annualized quarterly EPS was 0.7. Based on KPRX's history, that recent PE is elevated relative to the historical average, with the recent PE 75.0% higher than the historical average PE across our data set for Kiora Pharmaceuticals.

For self directed investors doing their due diligence on KPRX or any other given stock, valuation analysis for KPRX can greatly benefit from studying the past earnings and resulting PE ratio history calculations. This type of study can help inform an analysis as to whether the earnings trajectory over time and current versus historical average PE ratios justify the current stock market value.

That's why we bring you HistoricalPERatio.com to make it easy for investors to investigate Kiora Pharmaceuticals PE ratio history — or the PE history for any stock in our coverage universe. And in your continued research we hope you will be sure to check out the further links included for next earnings dates and also historical earnings surprises history for KPRX. Thanks for visiting, and the next time you need to research KPRX PE Ratio History or the PE ratio history for another stock, we hope our site will come to mind as your go-to PE ratio history research resource of choice.

Recommended: Top Ten Hedge Funds Holding PRLD, SPIB shares outstanding history, AVO Past Earnings.

 

KPRX PE Ratio History | www.HistoricalPERatio.com | Copyright © 2020 - 2022, All Rights Reserved

Nothing in HistoricalPERatio.com is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and market videos powered by Market News Video. Quote and option data delayed at least 15 minutes; stock quote data powered by Ticker Technologies, and Mergent.